Cellectis (CLLS) Now Covered by William Blair
William Blair initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research note published on Wednesday morning, MarketBeat reports. The firm issued an outperform rating on the biotechnology company’s stock.
Several other research firms also recently issued reports on CLLS. ValuEngine downgraded shares of Cellectis from a buy rating to a hold rating in a report on Friday, November 16th. Zacks Investment Research upgraded shares of Cellectis from a hold rating to a buy rating and set a $25.00 price objective on the stock in a report on Friday, November 16th. Oppenheimer set a $44.00 price objective on shares of Cellectis and gave the stock a buy rating in a report on Sunday, November 25th. BidaskClub downgraded shares of Cellectis from a sell rating to a strong sell rating in a report on Wednesday, November 21st. Finally, Barclays restated a buy rating and set a $50.00 price objective on shares of Cellectis in a report on Wednesday. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $32.00.
NASDAQ:CLLS opened at $19.31 on Wednesday. Cellectis has a 52-week low of $15.34 and a 52-week high of $38.85. The stock has a market cap of $792.48 million, a PE ratio of -10.01 and a beta of 1.76.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Recommended Story: What causes a recession?
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.